Business Description
Hansa Biopharma AB
ISIN : SE0002148817
Share Class Description:
LTS:0RC7: Ordinary SharesTotal Employee Number:
122Compare
Compare
Traded in other countries / regions
HNSA.Sweden0RC7.UK24H.GermanyHNSBF.USA IPO Date
2015-11-11Description
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.59 | |||||
Debt-to-Equity | N/A |
N/A
|
N/A
| |||
Debt-to-EBITDA | -2.11 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 0.67 | |||||
Beneish M-Score | -3.45 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -7.3 | |||||
3-Year EBITDA Growth Rate | 28.2 | |||||
3-Year EPS without NRI Growth Rate | 23.7 | |||||
3-Year FCF Growth Rate | 15.6 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 59.84 | |||||
9-Day RSI | 60.59 | |||||
14-Day RSI | 59.32 | |||||
3-1 Month Momentum % | -3.04 | |||||
6-1 Month Momentum % | -2.8 | |||||
12-1 Month Momentum % | 20.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.63 | |||||
Quick Ratio | 3.6 | |||||
Cash Ratio | 3.09 | |||||
Days Inventory | 20.47 | |||||
Days Sales Outstanding | 250.91 | |||||
Days Payable | 217.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -23.9 | |||||
Shareholder Yield % | -5.42 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 59.68 | |||||
Operating Margin % | -299.13 | |||||
Net Margin % | -361.44 | |||||
EBITDA Margin % | -284.56 | |||||
FCF Margin % | -286.33 | |||||
OCF Margin % | -286.33 | |||||
ROA % | -74.63 | |||||
ROIC % | -89.88 | |||||
3-Year ROIIC % | 13.23 | |||||
ROC (Joel Greenblatt) % | -4131.88 | |||||
ROCE % | -94.05 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 9.71 | |||||
PS Ratio | 16.27 | |||||
EV-to-EBIT | -7.28 | |||||
EV-to-EBITDA | -7.28 | |||||
EV-to-Revenue | 20.71 | |||||
EV-to-Forward-Revenue | 15.83 | |||||
EV-to-FCF | -7.23 | |||||
Price-to-GF-Value | 1.43 | |||||
Price-to-Median-PS-Value | 0.03 | |||||
Earnings Yield (Greenblatt) % | -13.74 | |||||
FCF Yield % | -15.68 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hansa Biopharma AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 190.486 | ||
| EPS (TTM) (kr) | -7.83 | ||
| Beta | 0.4211 | ||
| 3-Year Sharpe Ratio | 0.17 | ||
| 3-Year Sortino Ratio | 0.3 | ||
| Volatility % | 46.86 | ||
| 14-Day RSI | 59.32 | ||
| 14-Day ATR (kr) | 0.979573 | ||
| 20-Day SMA (kr) | 33.223507 | ||
| 12-1 Month Momentum % | 20.23 | ||
| 52-Week Range (kr) | 23.57 - 42.96 | ||
| Shares Outstanding (Mil) | 99.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hansa Biopharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hansa Biopharma AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 | In 121 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 121 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-22 | In 15 days | ||
| Second quarter earnings results for 2026 | 2026-07-22 | In 15 days | ||
| Hansa Biopharma Capital Markets Day | 2026-06-25 09:00 | 33.60 (-0.24%) | ||
| General meeting for 2026 | 2026-06-01 14:30 | 34.09 (+1.28%) | ||
| Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation | 2026-05-27 08:00 | 33.31 (-3.28%) | ||
| First quarter earnings conference call for 2026 | 2026-04-23 14:00 | 27.24 (-2.92%) | ||
| First quarter earnings results for 2026 | 2026-04-23 | 27.24 (-2.92%) | ||
| First quarter earnings conference call for 2026 | 2026-04-17 | 28.96 (-2.23%) |
Show
Entries
Hansa Biopharma AB Frequently Asked Questions
What is Hansa Biopharma AB(LTS:0RC7)'s stock price today?
The current price of LTS:0RC7 is kr35.05. The 52 week high of LTS:0RC7 is kr42.96 and 52 week low is kr23.57.
When is next earnings date of Hansa Biopharma AB(LTS:0RC7)?
The next earnings date of Hansa Biopharma AB(LTS:0RC7) is 2026-07-22.
Does Hansa Biopharma AB(LTS:0RC7) pay dividends? If so, how much?
Hansa Biopharma AB(LTS:0RC7) does not pay dividend.
Press Release
Articles on Hansa Biopharma AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers